Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-08-17

FDA Approved: RIFAMPIN — Supplemental Application (Lupin Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Rifampin from Lupin Pharmaceuticals, approving an addition or change to the existing Rifampin product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RIFAMPIN (RIFAMPIN)

Snippet

SUPPL AP for RIFAMPIN (RIFAMPIN)